DOCSLIB.ORG

Guidelines for Atcvet Classification 2010

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Guidelines for Atcvet Classification 2010 Guidelines for ATCvet classification 2010 ISSN 1020-9891 ISBN 978-82-8082-390-8 Suggested citation: WHO Collaborating Centre for Drug Statistics Methodology, Guidelines for ATCvet classification 2010. Oslo, 2010. © Copyright WHO Collaborating Centre for Drug Statistics Methodology, Oslo, Norway. Use of all or parts of the material requires reference to the WHO Collaborating Centre for Drug Statistics Methodology. Copying and distribution for commercial purposes is not allowed. Changing or manipulating the material is not allowed. Guidelines for ATCvet classification 12th edition WHO Collaborating Centre for Drug Statistics Methodology Norwegian Institute of Public Health P.O.Box 4404 Nydalen N-0403 Oslo Norway Telephone: +47 21078160 Telefax: +47 21078146 E-mail: [email protected] Website: www.whocc.no Previous editions: 1992: Guidelines on ATCvet classification, 1st edition1) 1995: Guidelines on ATCvet classification, 2nd edition1) 1999: Guidelines on ATCvet classification, 3rd edition1) 2002: Guidelines for ATCvet classification, 4th edition2) 2003: Guidelines for ATCvet classification, 5th edition2) 2004: Guidelines for ATCvet classification, 6th edition2) 2005: Guidelines for ATCvet classification, 7th edition2) 2006: Guidelines for ATCvet classification, 8th edition2) 2007: Guidelines for ATCvet classification, 9th edition2) 2008: Guidelines for ATCvet classification, 10th edition2) 2009: Guidelines for ATCvet classification, 10th edition2) 1) Published by the Nordic Council on Medicines 2) Published by the WHO Collaborating Centre for Drug Statistics Methodology Preface The Anatomical Therapeutic Chemical classification system for veterinary medicinal products, ATCvet, has been developed by the Nordic Council on Medicines (NLN) in collaboration with the NLN’s ATCvet working group, consisting of experts from the Nordic countries. The system is based on the same main principles as the ATC classification system for substances used in human medicine. The ATCvet system has been developed in association with the WHO Collaborating Centre for Drug Statistics Methodology in Oslo. The WHO Collaborating Centre for Drug Statistics Methodology is responsible for developing and maintaining the ATC system, and has since January 2001, also had the responsibility for the ATCvet classification system. The first edition of the Guidelines on ATCvet classification was published in 1992 followed by revised editions in 1995 and in 1999. These guidelines attracted international interest and have also been used to classify veterinary medicinal products outside, as well as inside, the Nordic region. The ATCvet classification system will be continuously revised in line with the ATC system and in response to the expanding range of preparations available in the field of veterinary medicine. Details of the classification codes assigned to all the substances classified can be found in the ATCvet Index, which is issued annually. The Guidelines on ATCvet classification, which also are revised annually, are needed to explain and provide comments on the classifications recommended. Copies of the Guidelines and the Index can be ordered from the WHO Collaborating Centre for Drug Statistics Methodology. The ATCvet Index, as well as further information about the ATCvet classification system, is also available on the Internet, at the website of the WHO Collaborating Centre, http://www.whocc.no. The ATCvet Working Group has at present the following members: Anders Eriksson Minerva Foundation for Medical Research, Finland Beat Gassner Swissmedic, Switzerland Kari Grave Norwegian School of Veterinary Science, Norway Vibeke Frøkjær Jensen Danish Institute of Food and Veterinary Research, Denmark Cristina Muñoz Madero Spanish Agency of Medicines and Medical Devices, Spain Stephan Steuber BVL (Bundesamt für Verbraucherschutz und Lebensmittelsicherheit), Germany WHO Collaborating Centre for Drug Statistics Methodology Oslo, January 2010 Christian Berg, MSc Pharm/MPH Irene Litleskare, MSc Pharm Marit Rønning, MSc Pharm Tove Granum, secretary WHO Collaborating Centre for Drug Statistics Methodology Norwegian Institute of Public Health Contents 1 Introduction to the ATCvet classification system ............................................ 11 1.1 History of the ATC/DDD- and the ATCvet systems................................... 11 1.2 The purpose of the ATCvet classification system ....................................... 11 1.3 Relationship between the ATCvet system and the ATC system for medicines for human use ............................................................................. 12 1.4 The ATCvet classification systems.............................................................. 12 2. Classification principles...................................................................................... 14 2.1 General principles ........................................................................................ 14 2.2 Classification of plain preparations ............................................................. 16 2.3 Classification of combination products ....................................................... 17 3. Procedures and data requirements for ATCvet classifications and alterations............................................................................................................. 18 3.1 Classification of new substances and data requirements ............................. 18 3.2 Principles regarding alterations to the ATCvet system................................ 19 3.3 Reporting...................................................................................................... 19 4. ATCvet Index....................................................................................................... 20 5. References ............................................................................................................ 20 6. ATCvet main groups........................................................................................... 21 QA - Alimentary tract and metabolism........................................................................ 21 This group comprises preparations used for the treatment of diseases affecting the alimentary tract or metabolism, e.g. antacids and antiemetics. It also includes e.g. antispasmodic and anticholinergic agents, vitamins and drugs used in diabetes. QB - Blood and blood forming organs ........................................................................ 39 The group QB comprises preparations mainly affecting the blood or the blood forming organs. For example, it includes antithrombotic agents, antianemic preparations and plasma substitutes. QC - Cardiovascular system........................................................................................ 45 This group comprises preparations used in the treatment of diseases affecting the cardiovascular system, or whose action is believed to be mediated mainly via the cardiovascular system. Included are, for example, antihypertensives and drugs for cardiac diseases. QD - Dermatologicals.................................................................................................. 59 This main group comprises dermatological preparations. Most of these preparations are intended for topical use, e.g. antifungals, antibiotics, corticosteroids and antiseptics for topical use. QG - Genito-urinary system and sex hormones........................................................... 71 The group QG comprises gynecological antiinfectives and antiseptics for local and intravaginal/intrauterine use. In addition e.g. urologicals and hormonal contraceptives are included. QH - Systemic hormonal preparations, excl. sex hormones and insulins.................... 83 This group comprises hormonal preparations for systemic use, excluding sex hormones and insulins. Included are also, for example, pancreatic hormones and hormonal preparations acting on calcium homeostasis. QI - Immunologicals................................................................................................... 89 This group comprises immunologicals for veterinary use and includes vaccines, immune sera and immunoglobulins. The group QI does not correspond to the ATC classification of immunologicals for human use. QJ - Antiinfectives for systemic use .......................................................................... 115 Group QJ comprises antiinfectives, antibacterials and antimycobacterials for systemic and intramammary use. Antiinfectives for local use are classified in other groups. QL - Antineoplastic and immunomodulating agents................................................. 129 The group QL comprises preparations, e.g. alkylating agents, antimetabolites, plant alkaloids and cytotoxic antibiotics, used in the treatment of malignant neoplastic diseases. Immunomodulating agents, both stimulating and suppressive agents, are also classified here. QM - Musculo-skeletal system.................................................................................... 135 Preparations used for the treatment of disease in or symptoms of the musculo-skeletal system can be classified in this group. Many drugs classified in this group, as the antiinflammatory agents, commonly affect other organs as well. Included are both topical preparations and products for systemic use. QN - Nervous system.................................................................................................. 141 Preparations affecting the nervous system, both centrally and peripherally, are classified in this group.
Load more

Recommended publications
  • Activity of Vancomycin Combined with Linezolid Against Clinical Vancomycin-Resistant Enterococcus Strains
    Basic research Activity of vancomycin combined with linezolid against clinical vancomycin-resistant Enterococcus strains Gulseren Aktas Department of Medical Microbiology, Faculty of Medicine, Istanbul University, Corresponding author: Istanbul, Turkey Gulseren Aktas Department of Medical Submitted: 16 April 2019 Microbiology Accepted: 12 July 2019 Faculty of Medicine Istanbul University Arch Med Sci Istanbul, Turkey DOI: https://doi.org/10.5114/aoms.2020.96400 Phone: 090 212 Copyright © 2020 Termedia & Banach 4142000/32417 Fax: 090 212 4142037 E-mail: Abstract [email protected] Introduction: Because multi-drug-resistant Gram-positive bacteria have been isolated frequently worldwide and are difficult to treat, alternative treatment choices are required. Combination antibiotherapies have a distinct advan- tage over monotherapies in terms of their broad spectrum and synergistic effect. In the present study, it was aimed to investigate the in vitro activity of vancomycin combined with linezolid against clinical vancomycin-resistant enterococci (VRE) strains with high-level aminoglycoside resistance. Material and methods: A total of 30 randomly selected clinical VRE strains were studied. Susceptibility to agents tested was investigated using broth microdilution assay. The inoculum of strain was adjusted to approximately 5 × 105 CFU/ml in the wells. The results were interpreted in accordance with Clinical and Laboratory Standards Institute guidelines. In vitro activities of anti biotics in combination were assessed using the broth microcheckerboard technique. The fractional inhibitory concentration indexes (FICIs) were inter- preted as follows: synergism, FICI ≤ 0.5; additive/indifference, FICI ≤ 0.5 – ≤ 4; antagonism, FICI > 4. Results: All strains were resistant to vancomycin and susceptible to linezolid. The MIC50,90 and MICrange values of antimicrobials were 512, 512, and 512–1024 µg/ ml for vancomycin; 2, 2, and 2–4 µg/ml for linezolid.
    [Show full text]
  • Medical Review(S) Clinical Review
    CENTER FOR DRUG EVALUATION AND RESEARCH APPLICATION NUMBER: 200327 MEDICAL REVIEW(S) CLINICAL REVIEW Application Type NDA Application Number(s) 200327 Priority or Standard Standard Submit Date(s) December 29, 2009 Received Date(s) December 30, 2009 PDUFA Goal Date October 30, 2010 Division / Office Division of Anti-Infective and Ophthalmology Products Office of Antimicrobial Products Reviewer Name(s) Ariel Ramirez Porcalla, MD, MPH Neil Rellosa, MD Review Completion October 29, 2010 Date Established Name Ceftaroline fosamil for injection (Proposed) Trade Name Teflaro Therapeutic Class Cephalosporin; ß-lactams Applicant Cerexa, Inc. Forest Laboratories, Inc. Formulation(s) 400 mg/vial and 600 mg/vial Intravenous Dosing Regimen 600 mg every 12 hours by IV infusion Indication(s) Acute Bacterial Skin and Skin Structure Infection (ABSSSI); Community-acquired Bacterial Pneumonia (CABP) Intended Population(s) Adults ≥ 18 years of age Template Version: March 6, 2009 Reference ID: 2857265 Clinical Review Ariel Ramirez Porcalla, MD, MPH Neil Rellosa, MD NDA 200327: Teflaro (ceftaroline fosamil) Table of Contents 1 RECOMMENDATIONS/RISK BENEFIT ASSESSMENT ......................................... 9 1.1 Recommendation on Regulatory Action ........................................................... 10 1.2 Risk Benefit Assessment.................................................................................. 10 1.3 Recommendations for Postmarketing Risk Evaluation and Mitigation Strategies ........................................................................................................................
    [Show full text]
  • National Antibiotic Consumption for Human Use in Sierra Leone (2017–2019): a Cross-Sectional Study
    Tropical Medicine and Infectious Disease Article National Antibiotic Consumption for Human Use in Sierra Leone (2017–2019): A Cross-Sectional Study Joseph Sam Kanu 1,2,* , Mohammed Khogali 3, Katrina Hann 4 , Wenjing Tao 5, Shuwary Barlatt 6,7, James Komeh 6, Joy Johnson 6, Mohamed Sesay 6, Mohamed Alex Vandi 8, Hannock Tweya 9, Collins Timire 10, Onome Thomas Abiri 6,11 , Fawzi Thomas 6, Ahmed Sankoh-Hughes 12, Bailah Molleh 4, Anna Maruta 13 and Anthony D. Harries 10,14 1 National Disease Surveillance Programme, Sierra Leone National Public Health Emergency Operations Centre, Ministry of Health and Sanitation, Cockerill, Wilkinson Road, Freetown, Sierra Leone 2 Department of Community Health, Faculty of Clinical Sciences, College of Medicine and Allied Health Sciences, University of Sierra Leone, Freetown, Sierra Leone 3 Special Programme for Research and Training in Tropical Diseases (TDR), World Health Organization, 1211 Geneva, Switzerland; [email protected] 4 Sustainable Health Systems, Freetown, Sierra Leone; [email protected] (K.H.); [email protected] (B.M.) 5 Unit for Antibiotics and Infection Control, Public Health Agency of Sweden, Folkhalsomyndigheten, SE-171 82 Stockholm, Sweden; [email protected] 6 Pharmacy Board of Sierra Leone, Central Medical Stores, New England Ville, Freetown, Sierra Leone; [email protected] (S.B.); [email protected] (J.K.); [email protected] (J.J.); [email protected] (M.S.); [email protected] (O.T.A.); [email protected] (F.T.) Citation: Kanu, J.S.; Khogali, M.; 7 Department of Pharmaceutics and Clinical Pharmacy & Therapeutics, Faculty of Pharmaceutical Sciences, Hann, K.; Tao, W.; Barlatt, S.; Komeh, College of Medicine and Allied Health Sciences, University of Sierra Leone, Freetown 0000, Sierra Leone 8 J.; Johnson, J.; Sesay, M.; Vandi, M.A.; Directorate of Health Security & Emergencies, Ministry of Health and Sanitation, Sierra Leone National Tweya, H.; et al.
    [Show full text]
  • Erythromycin Versus Tetracycline for Treatment of Mediterranean Spotted Fever
    Arch Dis Child: first published as 10.1136/adc.61.10.1027 on 1 October 1986. Downloaded from Archives of Disease in Childhood, 1986, 61, 1027-1029 Erythromycin versus tetracycline for treatment of Mediterranean spotted fever T MUNOZ-ESPIN, P LOPEZ-PARtS, E ESPEJO-ARENAS, B FONT-CREUS, I MARTINEZ- VILA, J TRAVERIA-CASANOVA, F SEGURA-PORTA, AND F BELLA-CUETO Hospital de Sant Llatzer, Terrassa, Clinica Infantil del Nen Jesus, Sabadell, and Hospital Mare de Deu de la Salut, Sabadell, Barcelona, Spain SUMMARY Eighty one children aged between 1 and 13 years participated in a randomised comparative trial of tetracycline hydrochloride and erythromycin stearate for treatment of Mediterranean spotted fever. Both therapeutic regimens proved effective, but in patients treated with tetracycline both clinical symptoms and fever disappeared significantly more quickly. Likewise, when those patients who began treatment within the first 72 hours of illness are considered the febrile period had a significantly shorter duration in the group treated with tetracycline. One patient was switched to tetracycline because there was no improvement of clinical manifestations, with persistence of fever, myalgias, and prostration, after receiving eight days of treatment with erythromycin. These results suggest that tetracyclines are superior to erythromycin in the treatment of Mediterranean spotted fever. copyright. Mediterranean spotted fever is an acute infectious were not included in the trial; neither were those disease caused by Rickettsia conorii. During the
    [Show full text]
  • 4. Antibacterial/Steroid Combination Therapy in Infected Eczema
    Acta Derm Venereol 2008; Suppl 216: 28–34 4. Antibacterial/steroid combination therapy in infected eczema Anthony C. CHU Infection with Staphylococcus aureus is common in all present, the use of anti-staphylococcal agents with top- forms of eczema. Production of superantigens by S. aureus ical corticosteroids has been shown to produce greater increases skin inflammation in eczema; antibacterial clinical improvement than topical corticosteroids alone treatment is thus pivotal. Poor patient compliance is a (6, 7). These findings are in keeping with the demon- major cause of treatment failure; combination prepara- stration that S. aureus can be isolated from more than tions that contain an antibacterial and a topical steroid 90% of atopic eczema skin lesions (8); in one study, it and that work quickly can improve compliance and thus was isolated from 100% of lesional skin and 79% of treatment outcome. Fusidic acid has advantages over normal skin in patients with atopic eczema (9). other available topical antibacterial agents – neomycin, We observed similar rates of infection in a prospective gentamicin, clioquinol, chlortetracycline, and the anti- audit at the Hammersmith Hospital, in which all new fungal agent miconazole. The clinical efficacy, antibac- patients referred with atopic eczema were evaluated. In terial activity and cosmetic acceptability of fusidic acid/ a 2-month period, 30 patients were referred (22 children corticosteroid combinations are similar to or better than and 8 adults). The reason given by the primary health those of comparator combinations. Fusidic acid/steroid physician for referral in 29 was failure to respond to combinations work quickly with observable improvement prescribed treatment, and one patient was referred be- within the first week.
    [Show full text]
  • (12) Patent Application Publication (10) Pub. No.: US 2004/0224012 A1 Suvanprakorn Et Al
    US 2004O224012A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2004/0224012 A1 Suvanprakorn et al. (43) Pub. Date: Nov. 11, 2004 (54) TOPICAL APPLICATION AND METHODS Related U.S. Application Data FOR ADMINISTRATION OF ACTIVE AGENTS USING LIPOSOME MACRO-BEADS (63) Continuation-in-part of application No. 10/264,205, filed on Oct. 3, 2002. (76) Inventors: Pichit Suvanprakorn, Bangkok (TH); (60) Provisional application No. 60/327,643, filed on Oct. Tanusin Ploysangam, Bangkok (TH); 5, 2001. Lerson Tanasugarn, Bangkok (TH); Suwalee Chandrkrachang, Bangkok Publication Classification (TH); Nardo Zaias, Miami Beach, FL (US) (51) Int. CI.7. A61K 9/127; A61K 9/14 (52) U.S. Cl. ............................................ 424/450; 424/489 Correspondence Address: (57) ABSTRACT Eric G. Masamori 6520 Ridgewood Drive A topical application and methods for administration of Castro Valley, CA 94.552 (US) active agents encapsulated within non-permeable macro beads to enable a wider range of delivery vehicles, to provide longer product shelf-life, to allow multiple active (21) Appl. No.: 10/864,149 agents within the composition, to allow the controlled use of the active agents, to provide protected and designable release features and to provide visual inspection for damage (22) Filed: Jun. 9, 2004 and inconsistency. US 2004/0224012 A1 Nov. 11, 2004 TOPCAL APPLICATION AND METHODS FOR 0006 Various limitations on the shelf-life and use of ADMINISTRATION OF ACTIVE AGENTS USING liposome compounds exist due to the relatively fragile LPOSOME MACRO-BEADS nature of liposomes. Major problems encountered during liposome drug Storage in vesicular Suspension are the chemi CROSS REFERENCE TO OTHER cal alterations of the lipoSome compounds, Such as phos APPLICATIONS pholipids, cholesterols, ceramides, leading to potentially toxic degradation of the products, leakage of the drug from 0001) This application claims the benefit of U.S.
    [Show full text]
  • Data on Before and After the Traceability System of Veterinary Antimicrobial Prescriptions in Small Animals at the University Veterinary Teaching Hospital of Naples
    animals Article Data on before and after the Traceability System of Veterinary Antimicrobial Prescriptions in Small Animals at the University Veterinary Teaching Hospital of Naples Claudia Chirollo , Francesca Paola Nocera , Diego Piantedosi, Gerardo Fatone , Giovanni Della Valle, Luisa De Martino * and Laura Cortese Department of Veterinary Medicine and Animal Productions, University of Naples, “Federico II”, Via Delpino 1, 80137 Naples, Italy; [email protected] (C.C.); [email protected] (F.P.N.); [email protected] (D.P.); [email protected] (G.F.); [email protected] (G.D.V.); [email protected] (L.C.) * Correspondence: [email protected]; Tel.: +39-081-253-6180 Simple Summary: Veterinary electronic prescription (VEP) is mandatory by law, dated 20 November 2017, No. 167 (European Law 2017) Article 3, and has been implemented in Italy since April 2019. In this study, the consumption of antimicrobials before and after the mandatory use of VEP was analyzed at the Italian University Veterinary Teaching Hospital of Naples in order to understand how the traceability of antimicrobials influences veterinary prescriptions. The applicability and utility of VEP may present an effective surveillance strategy able to limit both the improper use of Citation: Chirollo, C.; Nocera, F.P.; antimicrobials and the spread of multidrug-resistant pathogens, which have become a worrying Piantedosi, D.; Fatone, G.; Della Valle, threat both in veterinary and human medicine. G.; De Martino, L.; Cortese, L. Data on before and after the Traceability Abstract: Over recent decades, antimicrobial resistance has been considered one of the most relevant System of Veterinary Antimicrobial issues of public health.
    [Show full text]
  • Antibiotic Use in Pregnancy and Lactation What Is and Is Not Known About Teratogenic and Toxic Risks
    Reviews Antibiotic Use in Pregnancy and Lactation What Is and Is Not Known About Teratogenic and Toxic Risks Gerard G. Nahum, MD, CAPT Kathleen Uhl, USPHS, and CAPT Dianne L. Kennedy, USPHS OBJECTIVE: Over ten million women are either pregnant icol, ciprofloxacin, doxycycline, levofloxacin, and or lactating in the United States at any time. The risks of rifampin) to “undetermined” (clindamycin, gentamicin, medication use for these women are unique. In addition and vancomycin). Assessments were based on “good to normal physiologic changes that alter the pharmaco- data” (penicillin G and VK), “fair data” (amoxicillin, chlor- kinetics of drugs, there is the concern of possible terato- amphenicol, ciprofloxacin, doxycycline, levofloxacin, and genic and toxic effects on the developing fetus and rifampin), “limited data” (clindamycin and gentamicin), newborn. This article reviews the risks and pharmacoki- and “very limited data” (vancomycin). Significant phar- netic considerations for 11 broad-spectrum antibiotics macokinetic changes occurred during pregnancy for the that can be used to treat routine and life-threatening penicillins, fluoroquinolones and gentamicin, indicating infections during pregnancy and lactation. that dosage adjustments for these drugs may be neces- sary. With the exception of chloramphenicol, all of these DATA SOURCES: Information from the U.S. Food and antibiotics are considered compatible with breastfeed- Drug Administration (FDA) product labels, the Teratogen ing. Information Service, REPROTOX, Shepard’s Catalog of Teratogenic Agents, Clinical Pharmacology, and the peer- CONCLUSION: Health care professionals should con- reviewed medical literature was reviewed concerning the sider the teratogenic and toxic risk profiles of antibiotics use of 11 antibiotics in pregnant and lactating women.
    [Show full text]
  • Subject Index
    52_1107_1136_SI 16.11.2005 9:35 Uhr Seite 1107 Subject Index A – tape 264, 368, 940 α-adjustment 154 AAS, see atomic absorption spectrophotometry adrenocorticotrophic hormone (ACTH) 21 abietic acid 909, 943 adverse drug reaction 401 abrasion 174, 283 aeroallergen 391 absorption through appendage 169 – atopic eczema 391 α-acaridial 329 – avoidance 391 accident 889 aerospace 726 acebutolol hydrochloride 909 African aceclofenac 909 –ebony783 acetaldehyde 943 – mahagony 783 acetone 118, 666 – red padauk wood 783 acetylacetone 697 Agave acetylsalicylic acid 84, 909 – americana 354 Achillea millefolium (yarrow extract) 909 – tequilana 225 aciclovir 909 age 279 acid 110 agent orange 806 – black 48 (CI 65005) 909 AGEP 404 – dye 689 Agfa TSS 355 – halogenated 259 aggravation 204 –hydrochloric261 agricultural worker 272 –nitric261 agriculture 725 –red AICD, see activation-induced cell death – – 14 (azorubine) 909 airborne – – 118 (CI 26410) 909 – allergic contact dermatitis 218, 228, 315, 467, 477, 484, 598, ––359909 627, 654, 788 – violet 17 (CI 42650) 909 – contact urticaria 753, 758 – yellow – irritant contact dermatitis 625 – – 36 (CI 13065, metanil yellow) 909 aircraft manufacture 560 – – 61 (CI 18968) 909 airway symptom 520 acitretin 341 alachlor 953 acneiform alantolactone 55, 789, 909, 954 – folliculitis 229 alclometasone-17,21-dipropionate 909 –lesion265 alclometasone-17-propionate 58 acrodermatitis enteropathica 241 alcohol, see also ethyl 909 acrovesicular dermatitis 401 aldehyde 110, 607, 886 acrylamide 592, 944 algicide 562 acrylate
    [Show full text]
  • Antibiotic Resistance in the European Union Associated with Therapeutic Use of Veterinary Medicines
    The European Agency for the Evaluation of Medicinal Products Veterinary Medicines Evaluation Unit EMEA/CVMP/342/99-Final Antibiotic Resistance in the European Union Associated with Therapeutic use of Veterinary Medicines Report and Qualitative Risk Assessment by the Committee for Veterinary Medicinal Products 14 July 1999 Public 7 Westferry Circus, Canary Wharf, London, E14 4HB, UK Switchboard: (+44-171) 418 8400 Fax: (+44-171) 418 8447 E_Mail: [email protected] http://www.eudra.org/emea.html ãEMEA 1999 Reproduction and/or distribution of this document is authorised for non commercial purposes only provided the EMEA is acknowledged TABLE OF CONTENTS Page 1. INTRODUCTION 1 1.1 DEFINITION OF ANTIBIOTICS 1 1.1.1 Natural antibiotics 1 1.1.2 Semi-synthetic antibiotics 1 1.1.3 Synthetic antibiotics 1 1.1.4 Mechanisms of Action 1 1.2 BACKGROUND AND HISTORY 3 1.2.1 Recent developments 3 1.2.2 Authorisation of Antibiotics in the EU 4 1.3 ANTIBIOTIC RESISTANCE 6 1.3.1 Microbiological resistance 6 1.3.2 Clinical resistance 6 1.3.3 Resistance distribution in bacterial populations 6 1.4 GENETICS OF RESISTANCE 7 1.4.1 Chromosomal resistance 8 1.4.2 Transferable resistance 8 1.4.2.1 Plasmids 8 1.4.2.2 Transposons 9 1.4.2.3 Integrons and gene cassettes 9 1.4.3 Mechanisms for inter-bacterial transfer of resistance 10 1.5 METHODS OF DETERMINATION OF RESISTANCE 11 1.5.1 Agar/Broth Dilution Methods 11 1.5.2 Interpretative criteria (breakpoints) 11 1.5.3 Agar Diffusion Method 11 1.5.4 Other Tests 12 1.5.5 Molecular techniques 12 1.6 MULTIPLE-DRUG RESISTANCE
    [Show full text]
  • Infant Antibiotic Exposure Search EMBASE 1. Exp Antibiotic Agent/ 2
    Infant Antibiotic Exposure Search EMBASE 1. exp antibiotic agent/ 2. (Acedapsone or Alamethicin or Amdinocillin or Amdinocillin Pivoxil or Amikacin or Aminosalicylic Acid or Amoxicillin or Amoxicillin-Potassium Clavulanate Combination or Amphotericin B or Ampicillin or Anisomycin or Antimycin A or Arsphenamine or Aurodox or Azithromycin or Azlocillin or Aztreonam or Bacitracin or Bacteriocins or Bambermycins or beta-Lactams or Bongkrekic Acid or Brefeldin A or Butirosin Sulfate or Calcimycin or Candicidin or Capreomycin or Carbenicillin or Carfecillin or Cefaclor or Cefadroxil or Cefamandole or Cefatrizine or Cefazolin or Cefixime or Cefmenoxime or Cefmetazole or Cefonicid or Cefoperazone or Cefotaxime or Cefotetan or Cefotiam or Cefoxitin or Cefsulodin or Ceftazidime or Ceftizoxime or Ceftriaxone or Cefuroxime or Cephacetrile or Cephalexin or Cephaloglycin or Cephaloridine or Cephalosporins or Cephalothin or Cephamycins or Cephapirin or Cephradine or Chloramphenicol or Chlortetracycline or Ciprofloxacin or Citrinin or Clarithromycin or Clavulanic Acid or Clavulanic Acids or clindamycin or Clofazimine or Cloxacillin or Colistin or Cyclacillin or Cycloserine or Dactinomycin or Dapsone or Daptomycin or Demeclocycline or Diarylquinolines or Dibekacin or Dicloxacillin or Dihydrostreptomycin Sulfate or Diketopiperazines or Distamycins or Doxycycline or Echinomycin or Edeine or Enoxacin or Enviomycin or Erythromycin or Erythromycin Estolate or Erythromycin Ethylsuccinate or Ethambutol or Ethionamide or Filipin or Floxacillin or Fluoroquinolones
    [Show full text]
  • Antimicrobial Resistance Benchmark 2020 Antimicrobial Resistance Benchmark 2020
    First independent framework for assessing pharmaceutical company action Antimicrobial Resistance Benchmark 2020 Antimicrobial Resistance Benchmark 2020 ACKNOWLEDGEMENTS The Access to Medicine Foundation would like to thank the following people and organisations for their contributions to this report.1 FUNDERS The Antimicrobial Resistance Benchmark research programme is made possible with financial support from UK AID and the Dutch Ministry of Health, Welfare and Sport. Expert Review Committee Research Team Reviewers Hans Hogerzeil - Chair Gabrielle Breugelmans Christine Årdal Gregory Frank Fatema Rafiqi Karen Gallant Nina Grundmann Adrián Alonso Ruiz Hans Hogerzeil Magdalena Kettis Ruth Baron Hitesh Hurkchand Joakim Larsson Dulce Calçada Joakim Larsson Marc Mendelson Moska Hellamand Marc Mendelson Margareth Ndomondo-Sigonda Kevin Outterson Katarina Nedog Sarah Paulin (Observer) Editorial Team Andrew Singer Anna Massey Deirdre Cogan ACCESS TO MEDICINE FOUNDATION Rachel Jones The Access to Medicine Foundation is an independent Emma Ross non-profit organisation based in the Netherlands. It aims to advance access to medicine in low- and middle-income Additional contributors countries by stimulating and guiding the pharmaceutical Thomas Collin-Lefebvre industry to play a greater role in improving access to Alex Kong medicine. Nestor Papanikolaou Address Contact Naritaweg 227-A For more information about this publication, please contact 1043 CB, Amsterdam Jayasree K. Iyer, Executive Director The Netherlands [email protected] +31 (0) 20 215 35 35 www.amrbenchmark.org 1 This acknowledgement is not intended to imply that the individuals and institutions referred to above endorse About the cover: Young woman from the Antimicrobial Resistance Benchmark methodology, Brazil, where 40%-60% of infections are analyses or results.
    [Show full text]